ReVivo Medical agreed upon clinical trial parameters with FDA that define a pathway to commercial sales for its anterior cervical plate and interbody cages.
The company plans to begin enrollment for the 50-patient clinical study in 2Q21 at two U.S. centers. Study participants will receive ReVivo Medical’s next-generation anterior cervical plate design and interbody cages used in anterior cervical discectomy and fusion.
Seed round funding, closed in 1Q20, will help support initial stages of the trial.
“Our goal at ReVivo Medical is to invent and bring to market medical devices that will improve patient outcomes and reduce healthcare costs.” says Gary Mittleman, President and CEO “Obtaining FDA market clearance is our next hurdle.”
“Our cervical plate and cage implants are designed to improve bone formation and achieve a superior rate and quality of fusion as compared to the commonly used devices of today,” said Eric Ledet, PhD., Chief Science Officer. “Additionally, the designs of our implants incorporate unique features that are intended to make them easier for the surgeon to use.”
ReVivo Medical agreed upon clinical trial parameters with FDA that define a pathway to commercial sales for its anterior cervical plate and interbody cages.
The company plans to begin enrollment for the 50-patient clinical study in 2Q21 at two U.S. centers. Study participants will receive ReVivo Medical’s next-generation anterior cervical...
ReVivo Medical agreed upon clinical trial parameters with FDA that define a pathway to commercial sales for its anterior cervical plate and interbody cages.
The company plans to begin enrollment for the 50-patient clinical study in 2Q21 at two U.S. centers. Study participants will receive ReVivo Medical’s next-generation anterior cervical plate design and interbody cages used in anterior cervical discectomy and fusion.
Seed round funding, closed in 1Q20, will help support initial stages of the trial.
“Our goal at ReVivo Medical is to invent and bring to market medical devices that will improve patient outcomes and reduce healthcare costs.” says Gary Mittleman, President and CEO “Obtaining FDA market clearance is our next hurdle.”
“Our cervical plate and cage implants are designed to improve bone formation and achieve a superior rate and quality of fusion as compared to the commonly used devices of today,” said Eric Ledet, PhD., Chief Science Officer. “Additionally, the designs of our implants incorporate unique features that are intended to make them easier for the surgeon to use.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.